Advertisement

Langenbecks Archiv für Chirurgie

, Volume 364, Issue 1, pp 413–417 | Cite as

76 a. Morbus Crohn: I. Möglichkeiten und Grenzen der konservativen Therapie

  • W. Domschke
B. Wissenschaftliches Programm I. Hauptthemen mit Aussprache F. Chirurgische Entscheidung auf gesicherter Grundlage b) Morbus Crohn
  • 24 Downloads

Zusammenfassung

Da die Ätiologie des Morbus Crohn nach wie vor unbekannt ist, bleibt die konservative wie chirurgische Therapie symptomatisch. Für die medikamentöse Behandlung eignen sich Prednisolon, Salazosulfapyridin, Metronidazol und Elementardiäten in Abhängigkeit von Lokalisation und Ausdehnung der Erkrankung. Die chirurgische Behandlung ist eine Therapie der Komplikationen: Stenosen, Fisteln, Abscedierungen. Weder nach konservativer noch nach chirurgischer Behandlung ist der weitere Verlauf vorhersehbar.

Schlüsselwörter

Therapie des Morbus Crohn Konservative Therapie Indikation zur Operation Chirurgisches Vorgehen 

Crohn's disease: Limits of medical therapy and indication for surgery

Summary

As the etiology of Crohn's disease is still unknown, medical as well as surgical treatment has to be symptomatic. Medical therapy is performed by use of prednisolone, salazosulfapyridine, metronidazole and elementary diet depending on the localisation and extension of the disease. Surgical treatment means therapy of complications like stenoses, fistulae and abscess formation. Neither after medical nor after surgical treatment the sourse of the disease is predictable.

Key words

Therapy of Crohn's disease Medical treatment Indication for surgery Surgical measures 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Dombal FT de, Burton IL, Clamp SE, Goligher JC (1974) Short-term course and prognosis of Crohn's disease. Gut 15:435–443PubMedGoogle Scholar
  2. 2.
    Mörl M, Zöberlein H-G, Classen M (1978) Morbus Crohn: Verlauf und Prognose bei 169 Kranken. Dtsch Med Wochenschr 103:1325–1329PubMedGoogle Scholar
  3. 3.
    Herfarth Ch (1983) Chronisch-entzündliche Darmerkrankungen - Indikation zur Operation. Z Gastroenterol 21: 27–34PubMedGoogle Scholar
  4. 4.
    Sales DJ, Kirsner JB (1983) The prognosis of inflammatory bowel disease. Arch Intern Med 143:294–299PubMedGoogle Scholar
  5. 5.
    Hefti ML (1981) Risiko- und Invaliditatsbeurteilung bei Morbus Crohn. Lebensvers Med 33:106–112Google Scholar
  6. 6.
    Malchow H, Riker U, Dietz K (1981) Lebenserwartung bei Morbus Crohn. Lebensvers Med 33:27–30Google Scholar
  7. 7.
    Khosla R, Willoughby CP, Jewell DP (1984) Crohn's disease and pregnancy. Gut 25:52–56PubMedGoogle Scholar
  8. 8.
    Best WR, Becktel JM, Singleton JWS, Kern F (1976) Development of a Crohn's disease activity index. Gastroenterology 70:439–444PubMedGoogle Scholar
  9. 9.
    Van Hees PAM, van Elteren PH, van Lier HJJ, van Tongeren JAM (1980) An index of inflammatory activity in patients with Crohn's disease. Gut 21:279–296PubMedGoogle Scholar
  10. 10.
    Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW (1979) National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 77:847–869PubMedGoogle Scholar
  11. 11.
    Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H (1984) European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 86:249–266PubMedGoogle Scholar
  12. 12.
    Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer Ch, Klotz U, Honoré Hansen S, Hvidberg EF (1983) Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 85:1350–1353PubMedGoogle Scholar
  13. 13.
    Saverymuttu S, Keshavarzian A, Gupta S, Donovan B, Hodgson HJF (1984) Evaluation of short term treatment of Crohn's disease with slow release 5-aminosalicylic acid. Gut 25: A 552Google Scholar
  14. 14.
    Van Hees PAM, van Lier HJJ, van Elteren PH, Driessen WMM, van Hogezand RA, ten Velde GPM, Bakker JH, van Tongeren JHM (1981) Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 22:404–409PubMedGoogle Scholar
  15. 15.
    Ursing B, Alm T, Bárány F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Järnerot G, Krause U, Krook A, Lindström B, Nordle Ö, Rosén A (1982) A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 83:550–562PubMedGoogle Scholar
  16. 16.
    Gall FP, Mühe E, Angermann B (1983) Resultate operativer Therapie des Morbus Crohn. In: Ottenjann R, Fahrländer H (Hrsg) Entzündliche Erkrankungen des Dickdarms. Springer, Berlin Heidelberg New York, S 287–295Google Scholar
  17. 17.
    Bernstein LH, Frank MS, Brandt LJ, Boley SJ (1980) Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79:357–365Google Scholar
  18. 18.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 83:383–387PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • W. Domschke
    • 1
  1. 1.Medizinische Klinik mit Poliklinik der Universität ErlangenErlangen

Personalised recommendations